IRIS

Sfoglia per Titolo

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 2.124 a 2.143 di 16.181
Titolo Data di pubblicazione Autore(i) File
By-pass carotido-carotideo-suclavio con passaggio retrofraringeo nel trattamento ibrido degli aneurismi della porzione distale dell'arco aortico. 1-gen-2008 Spinelli, F.; Stilo, F.; La Spada, M.; De Caridi, G.; Benedetto, F.; Carella., G.
Bypass for symptomatic in-stent carotid restenosis. 1-gen-2017 Stilo, F; Sirignano, P; Montelione, N; Mansour, W; Capoccia, L; Catanese, V; Spinelli, F; Speziale, F.
Bypass Surgery for the Treatment of Upper Limb Chronic Ischaemia 1-gen-2010 Spinelli, F; Benedetto, F; Passari, G; La Spada, M; Carella, G; Stilo, F; De Caridi, G; Lentini, S
C metric: the equatorial plane and Fermi coordinates 1-gen-2005 Bini, D.; Cherubini, C.; Filippi, S; Geralico, A.
C-peptide and HbA1c levels at diagnosis indicate a different pathogenic process depending on the age at onset of Type 1 diabetes 1-gen-2004 Pozzilli, P; Pitocco, D; Visalli, N; Spera, S; Corbi, S; Suraci, C; Crino, A; Patera, P; Matteoli, Mc; Costanza, F; Fioriti, E; Ghirlanda, G; Cappa, M; Grp, I
C-peptide and HbA1c levels at diagnosis indicate a different pathogenic process depending on the age of onset of type 1 diabetes 1-gen-2004 Pozzilli, P; Visalli, N; Picardi, A; Manfrini, S; Crino, A; Suraci, C; Pitocco, D; Ghirlanda, G; Patera, P
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop (vol 53, pg 250, 2004) 1-gen-2004 Palmer, Jp; Fleming, Ga; Greenbaum, Cj; Herold, Kc; Jansa, Ld; Kolb, H; Lachin, Jm; Polonsky, Ks; Pozzilli, P; Skyler, Js; Steffes, Mw
C-peptide response and HLA genotype in subjects with recent onset type 1 diabetes following immunotherapy with DiaPep277 1-gen-2009 Buzzetti, R; Cernea, S; Petrone, A; Spoletini, M; Zampetti, S; Guglielmi, C; Venditti, C; Pozzilli, P
C-Peptide Response and HLA Genotypes in Subjects with Recent Onset Type 1 Diabetes Following Immunotherapy with Diapep277 1-gen-2009 Buzzetti, R; Cernea, S; Petrone, A; Spoletini, M; Zampetti, S; Guglielmi, C; Venditti, C; Pozzilli, P
C-Peptide response and HLA genotypes in subjects with recent onset type 1 diabetes following immunotherapy with diapep277 1-gen-2009 Buzzetti, R; Cernea, S; Petrone, A; Spoletini, M; Zampetti, S; Guglielmi, C; Venditti, C; Pozzilli, P
C-peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277 An Exploratory Study 1-gen-2011 Buzzetti, R; Cernea, S; Petrone, A; Capizzi, M; Spoletini, M; Zampetti, S; Guglielmi, C; Venditti, C; Pozzilli, P
C-peptide two years after diagnosis of Type 1 diabetes: the effect of nicotinamide and intensive insulin therapy 1-gen-2002 Visalli, N; Crino, A; Schiaffini, R; Matteoli, M; Patera, P; Pitocco, D; Ghirlanda, G; Manfrini, S; Suraci, C; Pozzilli, P
C-reactive protein "at first sight": Standard postoperative trend in gynecological surgery and a comparative analysis with white blood cell levels 1-gen-2023 De Cicco Nardone, Carlo; De Luca, Cristiana; Plotti, Francesco; Fabris, Silvia; Rossini, Gianmarco; Montera, Roberto; Luvero, Daniela; Angioli, Roberto; Terranova, Corrado
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD) 1-gen-2011 Corsonello, A; Pedone, C; Battaglia, S; Paglino, G; Bellia, V; Antonelli Incalzi, R
Ca 125 and fdg-pet in determining pathological complete response in ovarian cancer patients. 1-gen-2007 Perniola, G; Angioli, R; Basile, S; Palaia, I; Plotti, F; Graziano, M; Servodio, C; Pecorini, F; Montera, R; Muzii, L; Benedetti Panici, P.
CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis 1-gen-2021 Coppola, A; La Vaccara, V; Fiore, M; Farolfi, T; Ramella, S; Angeletti, S; Coppola, R; Caputo, D
CA2 Gene Polymorphisms Are Associated with Specific Eye Colour and Skin Phenotype in Type 1 Diabetes 1-gen-2010 Spoletini, M; Maggi, D; Zampetti, S; Astorri, E; Buzzetti, R; Pozzilli, P; Imdiab, G
Cabozantinib affects osteosarcoma growth through a direct effect on tumor cells and modifications in bone microenvironment 1-gen-2018 Fioramonti, M; Fausti, V; Pantano, F; Iuliani, M; Ribelli, G; Lotti, F; Pignochino, Y; Grignani, G; Santini, D; Tonini, G; Vincenzi, B
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 1-gen-2020 Iacovelli, R; Ciccarese, C; Facchini, G; Milella, M; Urbano, F; Basso, U; De Giorgi, U; Sabbatini, R; Santini, D; Berardi, R; Santoni, M; Bracarda, S; Massari, F; Masini, C; De Tursi, M; Ricotta, R; Buti, S; Zustovich, F; Sepe, P; Rossetti, S; Maruzzo, M; Cortesi, E; Tortora, G; Procopio, G
Cabozantinib and apixaban: an hitherto unreported interaction 1-gen-2019 Santini, D; Citarella, F; Vincenzi, B; Russano, M; Tonini, G; Stellato, M
Mostrati risultati da 2.124 a 2.143 di 16.181
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile